Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03653507
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-07-17T00:09:18.580530+00:00
Published At
2025-01-27T00:00:00+00:00
Record Updated At
2026-07-16
Results Posted At
2025-01-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-07-16"
protocolSection.identificationModule.nctId
"NCT03653507"
protocolSection.identificationModule.officialTitle
"A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-01-27"

Study condition terms

  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer (protocolSection.conditionsModule.conditions)
  • Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Gastric Adenocarcinoma or Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.